title: Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice.
abstract: Arginine-vasopressin (AVP) is known to be involved in maintaining glucose homeostasis, and AVP-resistance is observed in poorly controlled non-insulin-dependent diabetes mellitus subjects, resulting in a lowered plasma volume. Recently we reported that V1a vasopressin receptor-deficient (V1aR(-/-)) mice exhibited a decreased circulating blood volume and hypermetabolism of fat accompanied with impaired insulin-signaling. Here we further investigated the roles of the AVP/V1a receptor in regulating glucose homeostasis and plasma volume using V1aR(-/-) mice. The plasma glucose levels at the baseline or during a glucose tolerance test were higher in V1aR(-/-) than wild-type (WT) mice. Moreover, a hyperinsulinemic-euglycemic clamp revealed that the glucose infusion rate was significantly lower in V1aR(-/-) mice than in WT mice and that hepatic glucose production was higher in V1aR(-/-) mice than WT mice. In contrast to the increased hepatic glucose production, the liver glycogen content was decreased in the mutant mice. These results indicated that the mutant mice had impaired glucose tolerance. Furthermore, feeding V1aR(-/-) mice a high-fat diet accompanied by increased calorie intake resulted in significantly overt obesity in comparison with WT mice. In addition, we found that the circulating plasma volume and aldosterone level were decreased in V1aR(-/-) mice, although the plasma AVP level was increased. These results suggested that the effect of AVP on water recruitment was disturbed in V1aR(-/-) mice. Thus, we demonstrated that one of the AVP-resistance conditions resulting from deficiency of the V1a receptor leads to decreased plasma volume as well as impaired glucose homeostasis, which can progress to obesity under conditions of increased calorie intake.
authors.affiliation: Department of Pharmacology, National Research Institute for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo 157-8535, Japan.
authors.forename: Toshinori
authors.initials: T
authors.lastname: Aoyagi
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Birumachi
authors.forename: Masami
authors.initials: M
authors.lastname: Hiroyama
authors.forename: Yoko
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sanbe
authors.forename: Junji
authors.initials: J
authors.lastname: Yamauchi
authors.forename: Akito
authors.initials: A
authors.lastname: Tanoue
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000502:physiology; D004041:Dietary Fats / Q000494:pharmacology; D002149:Energy Intake / Q000502:physiology; D005247:Feeding Behavior / Q000502:physiology; D006003:Glycogen / Q000378:metabolism; D006706:Homeostasis / Q000502:physiology*; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology*; D010953:Plasma Volume / Q000502:physiology; D017483:Receptors, Vasopressin / Q000235:genetics* / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D007328:Insulin; D020738:Leptin; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D006003:Glycogen